Linagliptin

From WikiProjectMed
Jump to navigation Jump to search
Linagliptin
Linagliptin.svg
Names
Pronunciation/ˌlɪnəˈɡlɪptɪn/ LIN-ə-GLIP-tin
Trade namesTradjenta, Trajenta, others
Other namesBI-1356
  • 8-[(3R)-3-Aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
Clinical data
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
use		By mouth (tablets)
Defined daily dose5 mg[1]
External links
AHFS/Drugs.comMonograph
MedlinePlusa611036
Legal
License data
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetics
Bioavailability~30% (Tmax = 1.5 hours)
Protein binding75–99% (concentration-dependent)
MetabolismMinimal (~10% metabolized)
MetabolitesPharmacologically inactive
Elimination half-life~24 hours
ExcretionFeces (80%), urine (5%)[2]
Chemical and physical data
FormulaC25H28N8O2
Molar mass472.553 g·mol−1
3D model (JSmol)
  • CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
  • InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1 ☒N
  • Key:LTXREWYXXSTFRX-QGZVFWFLSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat diabetes mellitus type 2.[3] It is generally less preferred than metformin and sulfonylureas as an initial treatment.[3][4] It is used together with exercise and diet.[3] It is not recommended in type 1 diabetes.[3] It is taken by mouth.[3]

Common side effects include inflammation of the nose and throat.[3] Serious side effects may include angioedema, pancreatitis, joint pain.[4][3] Use in pregnancy and breastfeeding is not recommended.[4] Linagliptin is a dipeptidyl peptidase-4 inhibitor.[3] It works by increasing the production of insulin and decreasing the production of glucagon by the pancreas.[3]

Linagliptin was approved for medical use in the United States in 2011.[3] A month supply in the United Kingdom costs the NHS about £33 as of 2019.[4] In the United States the wholesale cost of this amount is about 391 USD.[5] In 2017, it was the 200th most commonly prescribed medication in the United States, with more than two million prescriptions.[6][7]

Medical uses

Results in 2010 from a Phase III clinical trial of linagliptin showed that the drug can effectively reduce blood sugar.[8]

Dosage

The defined daily dose is 5 mg by mouth.[1]

Side effects

Linagliptin may cause severe joint pain.[2][9]

The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines like sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors.

Trajenta's Prescribing Information[10] states the drug is contraindicated for people with bronchial hyperreactivity. Asthma is a form of bronchial hyperreactivity[11][circular reference].

Mechanism of action

Linagliptin belongs to a class of drugs called DPP-4 inhibitors.

Terminology

Linagliptin is the INN.[12]

Society and culture

Cost

A month supply in the United Kingdom costs the NHS about £33 as of 2019.[4] In the United States the wholesale cost of this amount is about 391 USD.[5] In 2017, it was the 200th most commonly prescribed medication in the United States, with more than two million prescriptions.[6][7]

  • Linagliptin costs (US)

  • Linagliptin prescriptions (US)

See also

References

  1. ↑ 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 8 September 2020. CS1 maint: discouraged parameter (link)
  2. ↑ 2.0 2.1 "Tradjenta (linagliptin) Tablets. Full Prescribing Information" (PDF). Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA. Retrieved 10 November 2016. CS1 maint: discouraged parameter (link)
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 "Linagliptin Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 6 April 2019. CS1 maint: discouraged parameter (link)
  4. ↑ 4.0 4.1 4.2 4.3 4.4 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 680. ISBN 9780857113382.
  5. ↑ 5.0 5.1 "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019. CS1 maint: discouraged parameter (link)
  6. ↑ 6.0 6.1 "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
  7. ↑ 7.0 7.1 "Linagliptin - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
  8. ↑ "Four Phase III Trials Confirm Benefits of BI's Oral, Once-Daily Type 2 Diabetes Therapy". Genetic Engineering & Biotechnology News. 28 June 2010.
  9. ↑ "DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain". FDA. 2015-08-28. Retrieved 1 September 2015. CS1 maint: discouraged parameter (link)
  10. ↑ https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Tradjenta/Tradjenta.pdf?DMW_FORMAT=pdf)
  11. ↑ Bronchial hyperresponsiveness
  12. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names: List 61" (PDF). World Health Organization. p. 66. Retrieved 10 November 2016. CS1 maint: discouraged parameter (link)


External links

External sites:
Identifiers:
Retrieved from "https://mdwiki.org/w/index.php?title=Linagliptin&oldid=1079463"